Search for content, post, videos

LEO Pharma appoints a new CEO

Christophe Bourdon

The company has announced the appointment of Christophe Bourdon as new Chief Executive Officer, effective April 1, 2022.

Christophe Bourdon joins from Orphazyme A/S where he has held the position as CEO since April 2021, following global leadership roles in both Amgen and Alexion.

Read more: LEO Pharma introduces a new operating model and organizational structure

“I am thrilled that Christophe Bourdon joins LEO Pharma as new CEO. Christophe Bourdon is an international and accomplished leader. I am confident that he is the right person to lead LEO Pharma’s transformation towards becoming a publicly listed leader in medical dermatology. The Board of Directors is looking forward to working closely with Christophe Bourdon and the Global Leadership Team on the next chapters of LEO Pharma’s growth journey,” says Chairman of the Board of Directors, Jesper Brandgaard.

Christophe Bourdon

Christophe Bourdon will join from a role as CEO of Orphazyme A/S. His previous roles include Senior Vice President, General Manager, U.S. Oncology Business, at US biotech Amgen Inc. where he also led commercialization planning of top-selling drugs on the global market. Prior to Amgen, Christophe Bourdon was Senior Vice President of Europe, Middle East, Africa, and Canada at Alexion as the company launched two breakthrough ultra-orphan drugs and negotiated payor access across UK, Germany, France, Italy, and Canada. Christophe Bourdon holds an MBA from IMD Business School (Switzerland) and a BA from ISG (France).

“I am excited to join LEO Pharma and bring my competences and experience into play as LEO Pharma goes through the next phases of its transformation. The company’s strong heritage appeals to me as well as the unique profile in medical dermatology. LEO Pharma has a huge potential for growth and for making a difference for people who need more treatment options for their skin conditions,” says Christophe Bourdon.

Photo of Christophe Bourdon: Alexion